Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets-Reference-Cited by-同舟云学术

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets

Published:2022-10-11 Issue:1 Volume:30 Page:179-186
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Cortese Rosa¹^ORCID,Battaglini Marco¹^ORCID,Sormani Maria Pia²,Luchetti Ludovico¹,Gentile Giordano¹^ORCID,Inderyas Maira¹,Alexandri Nektaria³^ORCID,De Stefano Nicola¹

Affiliation:

1. Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy

2. Department of Health Sciences University of Genoa and Ospedale Policlinico San Martino IRCCS Genoa Italy

3. Merck Group, Neurology and Immunology Darmstadt Hessen Delaware USA

Funder

Merck KGaA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15579

Reference24 articles.

1. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

2. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

3. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

4. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

5. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world analysis of brain atrophy in multiple sclerosis patients with an artificial intelligence based software tool;Neurological Research and Practice;2024-08-08

2. Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging;Neuroimaging Clinics of North America;2024-08

3. Interpretable and Intuitive Machine Learning Approaches for Predicting Disability Progression in Relapsing-Remitting Multiple Sclerosis Based on Clinical and Gray Matter Atrophy Indicators;Academic Radiology;2024-07

4. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis;Annals of Neurology;2024-05-23

5. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis;CNS Drugs;2024-03-15